Clinical Trial Search

Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…

Primary: BFI Score — 65.0; 57.2; 48.8; 41.5 units on a scale — p=0.289

Primary: Executive Language Functions — 31.6; 30.8; 33.7; 31.8 Mean outpoint by group at pre and post

Primary: Kinematics - Swing Phase Separation — 0.9; 0.6; 1.0 mm

Primary: Rate of Clinical Benefit of Patients Receiving Vorinostat/AI Combination Therapy According to RECIST — 60 percentage of patients

Primary: Change in Hyperpigmentation of the Face — .8; .3; .45; .56 units on a scale — p=0.05

Primary: Short Form-12 Physical Health — 44; 41 units on a scale — p=<0.27

Primary: Change From Baseline HbA1c After Six Months of Treatment in Patients With Type 2 Diabetes Mellitus — 10; 7; 12 participants — p=<0.05

Primary: Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in AST Levels) — 83; 86.4 percentage change from baseline

Primary: Change in Hemoglobin (Hb) From Baseline (Week 0) to Week 12 — 31.47; 31.92 gramm per liter (g/L)

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 14; 13 participants

Primary: Number of Cases of ABU That Are Treated Inappropriately With Antibiotics — 1.6; 0.6; 0.5; 0.6 cases/1,000 bed-days

Primary: Change From Baseline in Likert Response: "I Can Comfortably Wear my Lenses" at Day 30 — 6.1; 6.3; 1.5; 1.4 units on a scale

Primary: Hamilton Depression Rating Scale: Baseline — 20.93; 19.38 units on a scale

Primary: Change in Triglyceride Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group. — -34; 40 mg/dl — p=0.01